PROJECT SUMMARY/ABSTRACT
Children with nephrotic syndrome, especially those that have frequent relapses (FRNS) or are resistant to
steroid therapy (SRNS), are exposed to prolonged courses of steroids and other immunosuppressant
medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an
urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the
vagus nerve, which can be activated non-invasively by transcutaneous auricular vagus nerve stimulation
(taVNS), modulates the immune system by the inflammatory reflex and spleen. taVNS has become a therapy
of interest for treating chronic immune-mediated illnesses. The central hypothesis is that activation of the
inflammatory reflex via taVNS modulates the immune response, attenuates relapses and proteinuria, and
reduces reliance on immunosuppressant medications in children with nephrotic syndrome. The overarching
goal is to conduct a large scale, multicenter clinical trial to investigate the efficacy and safety of taVNS in the
treatment of nephrotic syndrome in children. To optimally prepare for this larger clinical trial, the objective of
this proposal is to conduct pilot clinical trials to evaluate the feasibility and tolerability of taVNS for the
treatment of nephrotic syndrome in children and generate preliminary data to guide power calculations for a
future larger study. In this context, the specific aims of this proposal are: (Aim 1) To determine the feasibility of
protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children; (Aim 2) To
establish proof of concept and generate effect sizes for treatment response outcomes in children with nephrotic
syndrome randomized to taVNS therapy compared with sham therapy; (Aim 3) To investigate the effects of
taVNS on immune markers in children with nephrotic syndrome. The proposed pilot study will enroll 30 children
with FRNS and 10 children with SRNS age 3-17 years from two sites in two parallel, double-blinded,
randomized placebo-controlled trials comparing five minutes of daily taVNS use with sham therapy for 26
weeks. To test for feasibility and tolerability of the clinical trial, the process of recruitment, adherence
, device
functionality, time and resource utilization, and
safety monitoring will be examined. Using pre-specified proof-
of-concept criteria, preliminary data gathered from this pilot study will then be used to determine whether a
subsequent larger main trial should move forward. Further,
immune markers including serum and monocyte-
stimulated cytokines and anti-nephrin antibodies will be measured in order to characterize the
immunomodulatory effect of taVNS therapy. To this end, accomplishing the goals of this pilot study will provide
preliminary data that will inform the design of and strengthen the implementation of a planned larger clinical
trial. Providing these preliminary data that are essential to conduct a large-scale trial will address a significant
knowledge gap and will pave the way for evaluation of an innovative, non-pharmacologic, non-invasive,
steroid-sparing approach to the treatment of idiopathic nephrotic syndrome in children.
